Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission

Basit Öğe Kaydı
dc.contributor.authorErdogan, Mehmet
dc.contributor.authorOzbek, Mustafa
dc.contributor.authorAkbal, Erdem
dc.contributor.authorUreten, Kemal
dc.date.accessioned2020-06-25T18:34:24Z
dc.date.available2020-06-25T18:34:24Z
dc.date.issued2019
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground/aim: Acromegaly is associated with increased morbidity and mortality, mostly due to cardiovascular complications. Plasma thrombin-activatablc fibrinolysis inhibitor (TAFI) antigen levels arc associated with coagulation/fibrinolysis and inflammation. Plasma TAFI may play a role in arterial thrombosis in cardiovascular diseases. In this study, it was aimed to evaluate the thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and homocysteine levels in patients with acromegaly and healthy control subjects. Materials and methods: Plasma TAFI antigen and homocysteine levels in 29 consecutive patients with acromegaly and 26 age-matched healthy control subjects were measured. All patients included in the study were in remission. The TAFIa/ai antigen in the plasma samples was measured using a commercially available ELISA kit. Results: Routine biochemical parameters, fasting blood glucose, prolactin, thyroid stimulating hormone, total-cholesterol, low density lipoprotein cholesterol, triglyceride, and homocysteine levels were similar in the 2 groups (P > 0.05), whereas the plasma TAFI antigen levels were significantly elevated in the acromegalic patients (154.7 +/- 94.0%) when compared with the control subjects (107.2 +/- 61.6%) (P = 0.033). No significant correlation was identified by Pearson's correlation test between the plasma TAFI antigen and homocysteine levels (r = 0.320, P = 0.250). Conclusion: A significant alteration in the plasma TAFI antigen levels was detected in acromegaly. Increased plasma TAFI antigen levels might aggravate prothrombotic and thrombotic events in patients with acromegaly.en_US
dc.identifier.citationErdoğan M., Özbek M., Akbal E.,Üreten K. (2019). Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission. Turkish Journal of Medical Sciences, 49(5), 1381 - 1385.en_US
dc.identifier.doi10.3906/sag-1812-231
dc.identifier.endpage1385en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5en_US
dc.identifier.pmid31549496
dc.identifier.scopus2-s2.0-85074117903
dc.identifier.scopusqualityQ1
dc.identifier.startpage1381en_US
dc.identifier.trdizinid336720
dc.identifier.urihttps://doi.org/10.3906/sag-1812-231
dc.identifier.urihttps://hdl.handle.net/20.500.12587/7899
dc.identifier.volume49en_US
dc.identifier.wosWOS:000504050500017
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTAFI antigenen_US
dc.subjectacromegalyen_US
dc.subjectcardiovascular diseaseen_US
dc.titlePlasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remissionen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
e491c33e-8536-4ec0-95a3-f05018f898bc.pdf
Boyut:
95.96 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu